Open AccessImplementing and delivering a successful biosimilar switch programme – the Berkshire West experience
Author(s) -
Antoni Chan,
Joanne Kitchen,
Amaka Scott,
David H. Pollock,
Richard P. Marshall,
Linda Herdman
Publication year - 2019
Publication title -
future healthcare journal
Language(s) - English
Resource type - Journals
eISSN - 2514-6653
pISSN - 2514-6645
DOI - 10.7861/futurehosp.6-2-143
Subject(s) - biosimilar , etanercept , psoriatic arthritis , rheumatoid arthritis , medicine , physical therapy , operations management , economics
Biosimilars used in multiple rheumatic conditions offer the -potential for cost savings. We present the outcomes of a -service evaluation of switching rheumatic patients established on originator etanercept (Enbrel) to biosimilar Benepali, using a managed switching programme funded through a novel fixed price incentivisation model.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom